Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Zika: WHO evaluates mosquito controls
aedes mosquito
Zika outbreaks are thought to be linked to serious birth defects and a rise in cases of
Guillain-Barré syndrome.
Release of sterile mosquitoes among possibilities 

The World Health Organisation (WHO) is evaluating a suite of new methods to control mosquito populations in a bid to tackle Zika virus, which is primarily spread by the Aedes aegypti mosquito.

Current possibilities include the introduction of genetically modified mosquitoes, or sterile male insects to suppress the population.

Zika was recently declared a global health emergency as it spread across the Americas. The outbreaks are thought to be linked to serious birth defects and a rise in cases of the autoimmune disorder, Guillain-Barré syndrome, though this has not yet been scientifically proven.

While 15 groups are currently working to develop a vaccine, WHO predicts it could take at least 18 months before large-scale trials can take place. With this in mind, the organisation is recommending better mosquito control as the best line of defence.

WHO has convened a vector control advisory group to consider new tools, including GM mosquitoes, which have previously been trialled in the Cayman Islands resulting in a significant decline in mosquito populations.

The group is backing further field trials and risk assessment to look into the potential impact on disease transmission.

Another strategy being developed is the release of sterile male insects so that when females mate with them, their eggs are not viable and the insect population dies out.

The release of males carrying the naturally occurring Wolbachia bacteria is another option. The bacteria does not affect humans or other mammals but prevents mosquito eggs hatching when females mate with affected males.

A different strain reduces the insect's capacity to spread dengue virus. Mosquitoes carrying the bacteria have already been released in a number of places, including Australia, Brazil, Indonesia and Vietnam as part of dengue control programmes. Large-scale field trials are expected to begin soon.

Meanwhile, WHO advocates the elimination of mosquito breeding sites as an effective intervention, as well as the use of insect repellents.

For more of the WHO's guidance, see: http://www.who.int/emergencies/zika-virus/articles/mosquito-control/en/

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.